Clinical

New research has identified how bone cells subdue cancer cells that have reached the bone so that the cancer cells remain dormant for decades. The finding may help researchers develop new treatments to prevent or treat metastatic disease and put cancer cells to sleep permanently.

Adults with relapsing multiple sclerosis (MS) who are treated with ozanimod have less gray matter volume loss than patients treated with interferon, according to a post hoc analysis from the phase 3 RADIANCE Part B trial. The research was presented at the 2019 American Academy of Neurology Annual Meeting.

Analyses of real-world data have broadened the understanding of multiple sclerosis (MS) and provided a snapshot into patient conditions and healthcare costs in the years leading up to and the years after an MS diagnosis, explained Bruce Pyenson, FSA, MAAA, Principal, Consulting Actuary, Milliman, Inc, during a session highlighting findings of a recent Milliman white paper at Asembia’s 15th annual Specialty Pharmacy Summit, held April 29 to May 2 in Las Vegas, Nevada.

In a session at Asembia's 15th annual Specialty Pharmacy Summit, held April 29 to May 2 in Las Vegas, speakers highlighted a pilot program to gather and use real-world evidence to compare outcomes at 7 large academic medical centers for patients with rheumatoid arthritis, multiple sclerosis, and malignant melanoma.

Currently, there is no universally accepted treatment standard for multiple sclerosis (MS), but 2 abstracts being presented at the American Academy of Neurology annual meeting evaluated the use and impact of highly effective therapies.

In the past 5 decades, there has been a steady rise in the prevalence of multiple sclerosis (MS), according to estimates using a validated algorithm across 5 large US administrative health claims data sets. The research was published in Neurology.

The challenge with translating good science into treatments for patients with multiple sclerosis (MS) is getting the funding to get the trials done, said Rhonda Voskuhl, MD, Jack H. Skirball chair of multiple sclerosis (MS) research, director of the MS program, and professor of neurology at the University of California, Los Angeles (UCLA).

Panelists discuss what PCSK9 inhibitors are, the evidence to support them, and challenges with operationalizing them in practice.

Pediatric multiple sclerosis (MS) represents a small minority of MS diagnoses. WIth symptoms that differ from adults, children with MS often experience delays before they are diagnosed.

A tool at Brigham and Women’s Hospital allows clinicians to view profiles of patients with multiple sclerosis (MS) as a snapshot to better understand their overall disease course, said Tanuja Chitnis, MD, associate neurologist at Brigham and Women’s Hospital and professor of neurology at Harvard Medical School.

Research comparing outcomes, resource utilization, and costs of multiple sclerosis (MS) found that patients with the disease face substantial burdens that differ among Japan, 5 European Union countries, and the United States.

Polypharmacy (patients taking ≥5 medications) is not uncommon in patients with relapsing-remitting multiple sclerosis and it is associated with higher levels of disability and the presence of comorbidities.

Minimal residual disease (MRD) is a strong prognosticator of cancer outcomes, and recent research found that patients with relapsed/refractory multiple myeloma (MM) are more likely to achieve MRD on daratumumab than on a standard of care alone.

There is not enough evidence that manual therapy—a clinical approach of using skilled, physical, hands-on procedures to improve function, lessen pain, and facilitate movement—can successfully be used to treat chronic obstructive pulmonary disease (COPD).

Two studies presented at the 60th American Society of Hematology Annual Meeting and Exposition examined patient preferences in multiple myeloma (MM) treatment and the importance of understanding these preferences when making treatment decisions.

Sephin1 provided protective benefits that delayed loss of myelin and onset of debilitating disease in mouse models of multiple sclerosis.

Treating patients with relapsing-remitting multiple sclerosis (MS) early with disease-modifying treatment can reduce the risk of conversion to secondary progressive MS.

For patients with multiple sclerosis (MS), upper extremity (UE) impairment is not uncommon, and patients with primary progressive MS tend to have a higher prevalence of UE dysfunction and greater impairment.

Patients with multiple sclerosis (MS) who are stable on an interferon β (INFβ) should remain on that therapy rather than switching to another INFβ, according to a study in ClinicoEconomics and Outcomes Research.